{"nctId":"NCT00782509","briefTitle":"12 / 48 wk Pivotal PFT vs PBO in COPD II","startDateStruct":{"date":"2009-02"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"count":644,"armGroups":[{"label":"Olodaterol (BI1744) Low","type":"EXPERIMENTAL","interventionNames":["Drug: Olodaterol (BI 1744)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Olodaterol (BI 1744) High","type":"EXPERIMENTAL","interventionNames":["Drug: Olodaterol (BI 1744)"]}],"interventions":[{"name":"Olodaterol (BI 1744)","otherNames":[]},{"name":"Olodaterol (BI 1744)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* All patients must have a diagnosis of chronic obstructive pulmonary disease\n* Male or female patients, 40 years of age or older Patients must be current or ex-smokers with a smoking history of more than 10 pack years Post bronchodilator FEV1 \\<80% predicted and post-bronchodilator FEV1/FVC \\<70%\n\nExclusion criteria:\n\n* Patients with a significant disease other than COPD\n* Patients with a history of asthma\n* Patients with any of the following conditions:\n\na history of myocardial infarction within 1 year of screening visit (Visit 1) unstable or life-threatening cardiac arrhythmia. have been hospitalized for heart failure within the past year. known active tuberculosis a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed) a history of life-threatening pulmonary obstruction a history of cystic fibrosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at Day 85 (12 Weeks)","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first am dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.008","spread":"0.013"},{"groupId":"OG001","value":"0.159","spread":"0.013"},{"groupId":"OG002","value":"0.152","spread":"0.013"}]}]}]},{"type":"PRIMARY","title":"Trough FEV1 Response at Day 85 (12 Weeks)","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.003","spread":"0.014"},{"groupId":"OG001","value":"0.044","spread":"0.014"},{"groupId":"OG002","value":"0.045","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in 1 Second (FEV1) Area Under Curve 0-12 h (AUC 0-12h) Response at Day 85 (12 Weeks)","description":"Response was defined as change from baseline. Study baseline FEV1 was defined as the mean of the available pre-dose FEV1 values prior to the first dose of randomized treatment. Means are adjusted using a non-mixed effects model with treatment (trt), tio stratum, baseline as fixed effects. FEV1 AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.010","spread":"0.021"},{"groupId":"OG001","value":"0.120","spread":"0.020"},{"groupId":"OG002","value":"0.100","spread":"0.020"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response At Day 1","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.025","spread":"0.013"},{"groupId":"OG001","value":"0.189","spread":"0.013"},{"groupId":"OG002","value":"0.196","spread":"0.013"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 2 Weeks","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.025","spread":"0.013"},{"groupId":"OG001","value":"0.188","spread":"0.013"},{"groupId":"OG002","value":"0.177","spread":"0.013"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 6 Weeks","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.010","spread":"0.013"},{"groupId":"OG001","value":"0.180","spread":"0.013"},{"groupId":"OG002","value":"0.171","spread":"0.013"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 24 Weeks","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.010","spread":"0.013"},{"groupId":"OG001","value":"0.155","spread":"0.013"},{"groupId":"OG002","value":"0.126","spread":"0.013"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response After 48 Weeks","description":"Response was defined as change from baseline. Baseline FEV1 was defined as the mean of the -1 h and -10 min measurements performed just prior to administration of the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit interaction as fixed categorical effects, baseline and baseline-by-visit interaction as fixed continuous covariates and patient as random effect. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.030","spread":"0.013"},{"groupId":"OG001","value":"0.132","spread":"0.013"},{"groupId":"OG002","value":"0.128","spread":"0.013"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response After 2 Weeks","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed a -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.013","spread":"0.014"},{"groupId":"OG001","value":"0.066","spread":"0.014"},{"groupId":"OG002","value":"0.078","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response After 6 Weeks","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.002","spread":"0.014"},{"groupId":"OG001","value":"0.071","spread":"0.014"},{"groupId":"OG002","value":"0.082","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response After 18 Weeks","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.007","spread":"0.014"},{"groupId":"OG001","value":"0.062","spread":"0.014"},{"groupId":"OG002","value":"0.037","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response After 24 Weeks","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.036","spread":"0.014"},{"groupId":"OG001","value":"0.033","spread":"0.014"},{"groupId":"OG002","value":"0.022","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response After 32 Weeks","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.029","spread":"0.014"},{"groupId":"OG001","value":"0.029","spread":"0.014"},{"groupId":"OG002","value":"-0.002","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response After 40 Weeks","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.029","spread":"0.014"},{"groupId":"OG001","value":"0.033","spread":"0.014"},{"groupId":"OG002","value":"0.043","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response After 48 Weeks","description":"Response was defined as change from baseline. Baseline trough FEV1 was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FEV1 is defined as the FEV1 performed at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FEV1s if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.057","spread":"0.014"},{"groupId":"OG001","value":"0.011","spread":"0.014"},{"groupId":"OG002","value":"0.014","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response At Day 1","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.099","spread":"0.014"},{"groupId":"OG001","value":"0.267","spread":"0.014"},{"groupId":"OG002","value":"0.276","spread":"0.013"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response After 2 Weeks","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.104","spread":"0.014"},{"groupId":"OG001","value":"0.259","spread":"0.014"},{"groupId":"OG002","value":"0.251","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response After 6 Weeks","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.080","spread":"0.014"},{"groupId":"OG001","value":"0.252","spread":"0.014"},{"groupId":"OG002","value":"0.246","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response After 12 Weeks","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.088","spread":"0.014"},{"groupId":"OG001","value":"0.232","spread":"0.014"},{"groupId":"OG002","value":"0.217","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response After 24 Weeks","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.062","spread":"0.014"},{"groupId":"OG001","value":"0.226","spread":"0.014"},{"groupId":"OG002","value":"0.197","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Peak FEV1 (0-3h) Response After 48 Weeks","description":"Response was defined as change from baseline. Baseline peak FEV1 was defined as the mean of the available pre-dose peak FEV1 values prior to first dose of randomized treatment. Peak FEV1 (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.041","spread":"0.014"},{"groupId":"OG001","value":"0.197","spread":"0.014"},{"groupId":"OG002","value":"0.198","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) Area Under Curve 0-3 Hours (AUC 0-3h) Response At Day 1","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.052","spread":"0.026"},{"groupId":"OG001","value":"0.383","spread":"0.026"},{"groupId":"OG002","value":"0.384","spread":"0.026"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) Area Under Curve 0-3 Hours (AUC 0-3h) Response After 2 Weeks","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.096","spread":"0.026"},{"groupId":"OG001","value":"0.338","spread":"0.026"},{"groupId":"OG002","value":"0.323","spread":"0.026"}]}]}]},{"type":"SECONDARY","title":"FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 6 Weeks","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.048","spread":"0.026"},{"groupId":"OG001","value":"0.312","spread":"0.027"},{"groupId":"OG002","value":"0.294","spread":"0.026"}]}]}]},{"type":"SECONDARY","title":"FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 12 Weeks","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.046","spread":"0.026"},{"groupId":"OG001","value":"0.284","spread":"0.027"},{"groupId":"OG002","value":"0.291","spread":"0.026"}]}]}]},{"type":"SECONDARY","title":"FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 24 Weeks","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.062","spread":"0.027"},{"groupId":"OG001","value":"0.303","spread":"0.027"},{"groupId":"OG002","value":"0.281","spread":"0.026"}]}]}]},{"type":"SECONDARY","title":"FVC Area Under Curve 0-3 Hours (AUC 0-3h) Response After 48 Weeks","description":"Response was defined as change from baseline. Baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect. FVC AUC 0-3h was calculated using the trapezoidal rule, divided by the observation time to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.053","spread":"0.027"},{"groupId":"OG001","value":"0.271","spread":"0.027"},{"groupId":"OG002","value":"0.271","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response After 2 Weeks","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.054","spread":"0.028"},{"groupId":"OG001","value":"0.113","spread":"0.028"},{"groupId":"OG002","value":"0.141","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response After 6 Weeks","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.029","spread":"0.028"},{"groupId":"OG001","value":"0.122","spread":"0.028"},{"groupId":"OG002","value":"0.147","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response After 12 Weeks","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.043","spread":"0.028"},{"groupId":"OG001","value":"0.075","spread":"0.028"},{"groupId":"OG002","value":"0.091","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response After 18 Weeks","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.064","spread":"0.028"},{"groupId":"OG001","value":"0.114","spread":"0.028"},{"groupId":"OG002","value":"0.098","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response After 24 Weeks","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.021","spread":"0.028"},{"groupId":"OG001","value":"0.066","spread":"0.028"},{"groupId":"OG002","value":"0.091","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response After 32 Weeks","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.061","spread":"0.028"},{"groupId":"OG001","value":"0.099","spread":"0.028"},{"groupId":"OG002","value":"0.058","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response After 40 Weeks","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.062","spread":"0.028"},{"groupId":"OG001","value":"0.104","spread":"0.028"},{"groupId":"OG002","value":"0.131","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response After 48 Weeks","description":"Response was defined as change from baseline. Baseline trough FVC was defined as the mean of the -1 hour and -10 minute measurements performed just prior to first dose of randomized treatment. Trough FVC is defined as the FVCs obtained at -10 mins prior to study drug inhalation as the end of the dosing interval or the mean of -1h and -10 min FVCs if both available. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.008","spread":"0.028"},{"groupId":"OG001","value":"0.038","spread":"0.028"},{"groupId":"OG002","value":"0.054","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"FVC Peak (0-3h) Response At Day 1","description":"Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours aftertreatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.202","spread":"0.027"},{"groupId":"OG001","value":"0.534","spread":"0.028"},{"groupId":"OG002","value":"0.535","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"FVC Peak (0-3h) Response After 2 Weeks","description":"Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.254","spread":"0.027"},{"groupId":"OG001","value":"0.479","spread":"0.028"},{"groupId":"OG002","value":"0.464","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"FVC Peak (0-3h) Response After 6 Weeks","description":"Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.183","spread":"0.028"},{"groupId":"OG001","value":"0.451","spread":"0.028"},{"groupId":"OG002","value":"0.434","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"FVC Peak (0-3h) Response After 12 Weeks","description":"Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.213","spread":"0.028"},{"groupId":"OG001","value":"0.439","spread":"0.028"},{"groupId":"OG002","value":"0.422","spread":"0.027"}]}]}]},{"type":"SECONDARY","title":"FVC Peak (0-3h) Response After 24 Weeks","description":"Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.223","spread":"0.028"},{"groupId":"OG001","value":"0.449","spread":"0.028"},{"groupId":"OG002","value":"0.429","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"FVC Peak (0-3h) Response After 48 Weeks","description":"Response was defined as change from baseline. Baseline FVC peak (0-3h) was defined as the mean of the available pre-dose FVC peak (0-3h) values prior to first dose of randomized treatment. FVC Peak (0-3h) values were obtained within 0 - 3 hours after treatment. Means are adjusted using a mixed effects model with treatment (trt), tio stratum, visit, trt-by-visit as fixed categorical effects, baseline and baseline-by-visit as fixed continuous covariates and patient as random effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.208","spread":"0.028"},{"groupId":"OG001","value":"0.415","spread":"0.028"},{"groupId":"OG002","value":"0.419","spread":"0.028"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) Area Under Curve 0-12 h (AUC 0-12h) Response at Day 85 (12 Weeks)","description":"Response was defined as change from baseline. Study baseline FVC was defined as the mean of the available pre-dose FVC values prior to the first dose of randomized treatment. Means are adjusted using a non-mixed effects model with treatment (trt), tio stratum, baseline as fixed effects. FVC AUC 0-12h was calculated from 0-12 hours post-dose using the trapezoidal rule, divided by the observation time (12h) to report in litres.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.057","spread":"0.036"},{"groupId":"OG001","value":"0.199","spread":"0.035"},{"groupId":"OG002","value":"0.212","spread":"0.036"}]}]}]},{"type":"SECONDARY","title":"Weekly Mean Pre-dose Morning Peak Expiratory Flow Rate (PEF)","description":"Weekly mean pre-dose morning peak expiratory flow rate (PEF) at 48 weeks. PEFR measurements recorded by means of an e-Diary on a daily basis. This e-Diary was used to record the twice daily PEFs, study drug use, and rescue salbutamol (albuterol) use. The best of three readings for each measurement was recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"182.939","spread":"3.800"},{"groupId":"OG001","value":"196.300","spread":"3.868"},{"groupId":"OG002","value":"203.873","spread":"3.757"}]}]}]},{"type":"SECONDARY","title":"Weekly Mean Evening Peak Expiratory Flow Rate (PEF)","description":"Weekly mean evening peak expiratory flow rate (PEF) at 48 weeks. PEFR measurements recorded by means of an e-Diary on a daily basis. This e-Diary was used to record the twice daily PEFs, study drug use, and rescue salbutamol (albuterol) use. The best of three readings for each measurement was recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"195.502","spread":"3.987"},{"groupId":"OG001","value":"207.958","spread":"4.065"},{"groupId":"OG002","value":"216.155","spread":"3.948"}]}]}]},{"type":"SECONDARY","title":"Weekly Mean of Daily Daytime Rescue Use","description":"The patient was to record in the e-Diary the number of puffs of salbutamol (albuterol) Metered-Dose Inhaler used each day and night. The weekly mean was calculated by taking the average of the number of puffs of rescue medication used each day during week 48.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.363","spread":"0.097"},{"groupId":"OG001","value":"0.947","spread":"0.099"},{"groupId":"OG002","value":"0.850","spread":"0.097"}]}]}]},{"type":"SECONDARY","title":"Weekly Mean of Daily Nighttime Rescue Use","description":"The patient was to record in the e-Diary the number of puffs of salbutamol (albuterol) Metered-Dose Inhaler used each day and night. The weekly mean was calculated by taking the average of the number of puffs of rescue medication used each night during week 48.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.072","spread":"0.121"},{"groupId":"OG001","value":"1.652","spread":"0.123"},{"groupId":"OG002","value":"1.312","spread":"0.120"}]}]}]},{"type":"SECONDARY","title":"Weekly Mean of Daily (24h) Rescue Use","description":"The patient was to record in the e-Diary the number of puffs of salbutamol (albuterol) Metered-Dose Inhaler used each day and night. The weekly mean was calculated by taking the average of the number of puffs of rescue medication used each 24 hour period during week 48.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.436","spread":"0.193"},{"groupId":"OG001","value":"2.599","spread":"0.197"},{"groupId":"OG002","value":"2.158","spread":"0.192"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Rating at Week 6","description":"Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"0.1"},{"groupId":"OG001","value":"3.0","spread":"0.1"},{"groupId":"OG002","value":"2.9","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Rating at Week 12","description":"Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"0.1"},{"groupId":"OG001","value":"2.9","spread":"0.1"},{"groupId":"OG002","value":"3.0","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Rating at Week 24","description":"Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"0.1"},{"groupId":"OG001","value":"3.0","spread":"0.1"},{"groupId":"OG002","value":"2.9","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Patient's Global Rating at Week 48","description":"Patients were asked to rate their respiratory condition relative to their condition prior to the first dose of study medication. The scale is a seven point scale: 1=very much better, 2=much better,3=a little better,4=no change,5=a little worse,6=much worse,7=very much worst.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"0.1"},{"groupId":"OG001","value":"3.1","spread":"0.1"},{"groupId":"OG002","value":"3.0","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation","description":"Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor. Due to the limited number of events some statistics were not able to be calculated and are listed as N/A or are blank.\n\nThe measured values presented are actually the First Quartile and 95% confidence interval.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"306.0","spread":null},{"groupId":"OG001","value":"259.0","spread":null},{"groupId":"OG002","value":"225.0","spread":null},{"groupId":"OG003","value":"315.0","spread":null},{"groupId":"OG004","value":"219.0","spread":null},{"groupId":"OG005","value":"216.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Leading to Hospitalization","description":"Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor. Due to the limited number of events some statistics were not able to be calculated and are listed as N/A or are blank. The measured values presented are actually the First Quartile and 95% confidence interval.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"NA","spread":null},{"groupId":"OG005","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Moderate Chronic Obstructive Pulmonary Disease (COPD) Exacerbation","description":"Qualifying events of COPD were specifically pre-defined in the protocol.Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Moderate exacerbations were defined as exacerbations which did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids. Time to event was measured from the beginning of treatment. Cox regression analysis of treatment effect using tiotropium stratum as a stratification factor.Due to the limited number of events some statistics were not able to be calculated and are listed as N/A or are blank. The measured values presented are actually the First Quartile and 95% confidence interval..","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"362.0","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"225.0","spread":null},{"groupId":"OG005","value":"308.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of COPD Exacerbations","description":"Mean number of COPD exacerbations per patient years. Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4590","spread":"0.0687"},{"groupId":"OG001","value":"0.5453","spread":"0.0765"},{"groupId":"OG002","value":"0.5885","spread":"0.0799"}]}]}]},{"type":"SECONDARY","title":"Number of COPD Exacerbations Requiring Hospitalization","description":"Mean number of COPD exacerbations requiring hospitalization per patient years. Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. These exacerbations required hospitalization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0786","spread":"0.0273"},{"groupId":"OG001","value":"0.0811","spread":"0.0268"},{"groupId":"OG002","value":"0.0886","spread":"0.0287"}]}]}]},{"type":"SECONDARY","title":"Number of Moderate Chronic Obstructive Pulmonary Disease (COPD) Exacerbations","description":"Mean number of moderate COPD exacerbations per patient years. Qualifying events of COPD were specifically pre-defined in the protocol. Other respiratory related events were evaluated by the investigator to see if they met the pre-defined criteria. Moderate exacerbations were defined as exacerbations which did not lead to hospitalization but included treatment with antibiotics and/or systemic steroids.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3375","spread":"0.0587"},{"groupId":"OG001","value":"0.4335","spread":"0.0699"},{"groupId":"OG002","value":"0.4513","spread":"0.0701"}]}]}]},{"type":"SECONDARY","title":"Changes in Safety Parameters Related to Treatment","description":"Occurence of bronchoconstriction, cardiac disorders and investigations related to treatment. Bronchoconstriction is defined as any of the following events: Drop in trough FEV1 \\>= 15%, Rescue medication use within 30 min of inhaling randomized treatment on a clinic test day or Cough, wheeze, or dyspnoea AE within 30 min of inhaling randomized treatment on a clinic test day.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.9","spread":null},{"groupId":"OG001","value":"3.3","spread":null},{"groupId":"OG002","value":"5.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"1.9","spread":null},{"groupId":"OG002","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Potassium","description":"Laboratory testing: Average change from baseline of potassium measured. The laboratory tests at Day 1 were considered the baseline measurements.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.4"},{"groupId":"OG001","value":"-0.0","spread":"0.4"},{"groupId":"OG002","value":"0.0","spread":"0.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":32,"n":216},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Upper respiratory tract infection","Headache"]}}}